Alzchem Group Ag · XETR:ACT
Alzchem — Q3 2025 Earnings Presentation
31 slides from Alzchem's earnings presentation, Oct 30, 2025
Slide 1: Agile Science Pure Results
AGILE SCIENCE PURE RESULTS
Slide 2: Q3 2025 presenters and date
3 2025 ANDREAS NIEDERMAIER, CEO DR. GEORG WEICHSELBAUMER, CSO ANDREAS LOSLER, CFO October 30, 2025
Slide 3: Disclaimer
DISCLAIMER CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available info
Slide 4: Agenda — Analyst Presentation Q3 2025: Executive Summary
AGENDA — ANALYST PRESENTATION Q3 2025 Executive Summary
Slide 5: Highlights
sm Group AG / October 2025 HIGHLIGHTS Alzchem with further growth in sales and EBITDA Revenue above previous year: + 2% for 9m + 6% for Q3 EBITDA margin with further improvements up to 20.3% Specialty Chemicals segment pushes growth: +9% revenue growth +16% EBITDA growth Outlook confirmed; Sales and
Slide 6: Creavitalis goes Food
© Azchem Group AG #88 Creavitalis’ goes Food Strategic Partnership with Ehrmann brings Creatine to Supermarket Shelves (ay Creatine in Everyday Nutrition — A New Application successfully implemented Creavitalis® — premium creatine “Made in Germany” — enters the functional food segment for the first
Slide 7: Agenda — Business and financial details
AGENDA — ANALYST PRESENTATION Q3 2025 ll. Business and financial details
Slide 8: Basics & Intermediates
NITRALZ® Berlka’ G CaD BASICS & INTERMEDIATES The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture. steel production and the automotive sector and as raw materials for the manufacture of
Slide 9: Basics & Intermediates Segment (in M€)
BASICS & INTERMEDIATES SEGMENT (in M€) Sales and EBITDA reductions on expected level SALES ANALYSIS >: Volume + 0.4% Q3 Q4 QI Q2 Q3 4 QI Q2 QZ 2023 2023 2024 2024 2024 2024 2025 2025 2025 COMMENTS om with Q3 04 Qi Q2 Q3 4 QI 2 Q3 2023 2023 2024 2024 2024 2024 2025 2025 2025 1-9 1-9 2024 2025
Slide 10: Specialty Chemicals
a eo ( CREAMINO Drmex' Bioselect®? DYHARD ##% Creapure* SPECIALTY CHEMICALS The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.
Slide 11: Specialty Chemicals Segment (in M€)
SPECIALTY CHEMICALS SEGMENT (in Mé€) Segments growth trend continued Q3 Q4- QI Q2 Q3_ 4 QI 2 Q3 2023 2023 2024 2024 2024 2024 2025 2025 2025 Q3 04 Qi Q2 Q3 4 QI 2 Q3 2023 2023 2024 2024 2024 2024 2025 2025 2025 LES ANALYSIS COMMENTS The substantial ¢ attributed to: vth in sales and EBITDA was mainly
Slide 12: Other & Holding
The "Other & Holding" segment offers infrastructure and energy supply services a at our locations for the chemicals segments and for external customers. a, . OTHER & HOLDING
Slide 13: Other & Holding Segment (in M€)
OTHER & HOLDING SEGMENT (in mé€) Regulated grid fees impact sales and result COMMENTS a, * Slight r chemical m reduced Q3 Q4- QI Q2 Q3_ 4 QI 2 Q3 2023 2023 2024 2024 2024 2024 2025 2025 2025 _ <2» —_ Q3 Q4. QI Q2- QB 4 QT Q2- QB 1-9 1-9 1-9 1-9 2023 2023 2024 2024 2024 2024 2025 2025 2025 2024 2025
Slide 14: Financial Overview
FINANCIAL OVERVIEW Robust growth in EBITDA and earnings SALES (in M€) 1 +6.5% +2.3% EBITDA (in M€) ; i +19.5% ' +12.2% EBITDA margin (in %) +2.4 pp +1.8 pp Earnings per Share (in €) : r +32.6% . +20.6% stand alone olume and pr wth on group level mpens sed en Volume er FTE following the growth and .
Slide 15: Balance Sheet & Cashflow
BALANCE SHEET & CASHFLOW Financial situation at positive net cash; increase in total assets “MS lance sheet KPIs (TE) 31.12.20: 30.09.2025 Deviation * Increase in balance sheet total resulting from increased CAPEX and customer grants Balang q Inventories Planned inventory increase in preparation for
Slide 16: Outlook 2025 (in M€)
OUTLOOK 2025 (in me) The forecast remains valid — Growth in sales and EBITDA COMMENTS * Outlook for 2025 confirmed growth . - eneer to approx. * Major assumptions are still valid 580.0 ME growth to approx * Sales Growth FC 2025 FC 2025
Slide 17: Financial Calendar
FINANCIAL CALENDAR Upcoming dates* NOV 12 NOV 13 NOV 24-25 DEC2 JAN 19 FEB5 FEB 27 MAR 5 APR 30 MAY 5 MAY 21 JUL 30 OCT 29 - “subject to change 2025 2025 2025 2025 2026 2026 2026 2026 2026 2026 2026 2026 2026 ey Berenberg Pan-European Discovery Conference USA (virtual) MKK — Miinchner Kapitalmarkt K
Slide 18: Feedback
FEEDBACK We appreciate your feedback Were your expectations met? Are you missing any content? WE APPRECIATE YOUR FEEDBACK! QR-Code aera]
Slide 19: Investor Relations contact
alzchem group Investor Relations T +49 8621 86-2888 F +49 8621 86-502888 ir@alzchem.com
Slide 20: Agenda — Back-Up
AGENDA — ANALYST PRESENTATION Q3 2025 lll. Back-Up
Slide 21: Balance Sheet
© Alzchem Group AG / October 2025 BALANCE SHEET Alzchem Group ALZCHIEM GROUP (IN TE) 3112.2024 30.09.2025 Deviat Intangible assets 3671 3,562 109 -3.0% Tangible assets 192,976 236,705 B79 22.7% Investment properties Right of use (assets) 4023 3,240 “183 19.5% Investments accounted for using the equi
Slide 22: Pension Accounting (IFRS)
PENSION ACCOUNTING (IFRS) Alzchem Group (M€) IN FINANCIAL PENSION SERVICE NET INTEREST PENSION PENSION PENSION DEFERRED PENSION STATEMENT PROVISION costs costs PAYMENTS REMEASURE- PROVISION TAX ASSETS LIABILITY 31.12.2024 A MENTS 30.09.2025 30.09.2025 FINANCIAL RESULT oc BALANCE SHEET P&L CASHFLOW,
Slide 23: Income Statement
© Alzchem Group AG / October 2025 INCOME STATEMENT Alzchem Group ALZCHEM GROUP (NTE) cous tone n0ne tenons noms aos aaas—_—Deton Q3) Revenue 150,064 136,191 128,937 139,040 142,879 137,266 8329 6% Increase (+) / Decrease (-) in inventories of finished goods and work in progress “6521 12682-4310 7,16
Slide 24: Income Statement
© Alzchem Group AG / October 2025 INCOME STATEMENT Alzchem Group ALZCHEM GROUPIN TE) 2 & Deviation (200) seca selma Daton von Revense ass? 7266 =~ CS SCOSCSCISCSSSC*~«wSS*C« Increase (+)/ Decrease -Jninventories of finshed goods and workinprogeess = =310.=24S OMA ser 1503362 Tae otter incone ame 3.8
Slide 25: Cashflow Statement
© Alzchem Group AG / October 2025 CASHFLOW STATEMENT Alzchem Group Q3 3 1-9 1-9 CASHFLOW {IN ME) 2024 2025 2024 2025 Consolidated earnings before taxes 17,393 22,634 54,495, 64,880 Depreciation on fixed and intangible assets 6,402 6,655 19,390 19,642 Decrease in pension provisions -5a7 612 1651 ~198
Slide 26: Segment Overview by Quarter
SEGMENT OVERVIEW BY QUARTER AX Alzchem Group v SALES YTD Q3 2025 SALES 04 Deviation PY (Q3) Py Actual Deviation PY (YOY) Te Te % Te Te Te % Basics & Intermediates 2,382 6% 132,074 121,552 -10,521 -8% Specialty Chemicals 8% 259,120 281,617 9% Other and Holding 6 23,998 21,655 Group Consolidation Alzc
Slide 27: Alzchem Group Locations
ALZCHEM GROUP LOCATIONS Production sites and sales companies COVENTRY (UK) ATLANTA (USA) 6 rc} < 6 § 3 @ © SALES COMPANY
Slide 28: Vertically integrated production of chemical products based on the NCN chain
© Alzchem Group AG / October 2025 Vertically integrated production of chemical products based on the NCN chain “VERBUND” — FULLY INTEGRATED BUSINESS MODEL us O O Segment Specialty Chemicals Segment Basics & Inter- mediates BENEFITS OF “VERBUND” * Full control of product quality and specifications *
Slide 29: Our Products and Markets
© Alzchem Group AG / October 2025 OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries SPECIALTY “ a x y = wi = () MAIN PRODUCTS DESCRIPTION ey END-MARKETS CREAMINO® Anutritional additive for poultry and pigs Feed additive §Creapure’ Creapure®, premium brand for cre
Slide 30: Our Products and Markets
© Alzchem Group AG / October 2025 OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries n w = a < n ae a ta oo Wi [= e OTHER & HOLDING MAIN PRODUCTS DESCRIPTION END-MARKETS \N Calcium carbide-based mixtures for hot metal desulphurization Cad Steel industry Guanidine
Slide 31: Key Share Data
© alzchem Group AG / October 2025 KEY SHARE DATA Share details as of October 28, 2025 SHARES OUTSTANDING LAST CLOSING PRICE MARKET CAPITALIZATION TICKER WKN ISIN LISTING STOCK MARKET SEGMENT DESIGNATED SPONSOR 10,176,335 EUR 154.20 EUR 1,569 m ACT A2YNT3 DEOOOA2YNT30 Frankfurt Stock Exchange — Prime